These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21910880)

  • 1. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.
    Pennell DJ; Carpenter JP; Roughton M; Cabantchik Z
    J Cardiovasc Magn Reson; 2011 Sep; 13(1):45. PubMed ID: 21910880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
    Smith GC; Alpendurada F; Carpenter JP; Alam MH; Berdoukas V; Karagiorga M; Ladis V; Piga A; Aessopos A; Gotsis ED; Tanner MA; Westwood MA; Galanello R; Roughton M; Pennell DJ
    J Cardiovasc Magn Reson; 2011 Jul; 13(1):34. PubMed ID: 21733147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia.
    Leonardi B; Margossian R; Colan SD; Powell AJ
    JACC Cardiovasc Imaging; 2008 Sep; 1(5):572-8. PubMed ID: 19356483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
    Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
    J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
    Porter JB; Wood J; Olivieri N; Vichinsky EP; Taher A; Neufeld E; Giardina P; Thompson A; Moore B; Evans P; Kim HY; Macklin EA; Trachtenberg F
    J Cardiovasc Magn Reson; 2013 May; 15(1):38. PubMed ID: 23688265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.
    Pennell DJ; Udelson JE; Arai AE; Bozkurt B; Cohen AR; Galanello R; Hoffman TM; Kiernan MS; Lerakis S; Piga A; Porter JB; Walker JM; Wood J;
    Circulation; 2013 Jul; 128(3):281-308. PubMed ID: 23775258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On myocardial siderosis and left ventricular dysfunction in hemochromatosis.
    Carpenter JP; Grasso AE; Porter JB; Shah F; Dooley J; Pennell DJ
    J Cardiovasc Magn Reson; 2013 Mar; 15(1):24. PubMed ID: 23509881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
    Alpendurada F; Smith GC; Carpenter JP; Nair SV; Tanner MA; Banya W; Dessi C; Galanello R; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2012 Jan; 14(1):8. PubMed ID: 22277065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.
    Tanner MA; Galanello R; Dessi C; Westwood MA; Smith GC; Nair SV; Anderson LJ; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2006; 8(3):543-7. PubMed ID: 16755844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients.
    El Beshlawy A; El Tagui M; Hamdy M; El Ghamrawy M; Azim KA; Salem D; Said F; Samir A; St Pierre T; Pennell DJ
    Ann Hematol; 2014 Mar; 93(3):375-9. PubMed ID: 23949317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal diastolic function and Global longitudinal strain in patients with Thalassemia Major on long term chelation therapy.
    Nadar SK; Daar S; Abdelmottaleb WA; Shaikh MM; Al Mahrouqi H; Al-Raiisi M; Hassan M; Al Rawahi B; Al Rahbi S
    Int J Cardiovasc Imaging; 2021 Feb; 37(2):643-649. PubMed ID: 32965605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major: A Multicenter Study.
    Casale M; Meloni A; Filosa A; Cuccia L; Caruso V; Palazzi G; Gamberini MR; Pitrolo L; Putti MC; D'Ascola DG; Casini T; Quarta A; Maggio A; Neri MG; Positano V; Salvatori C; Toia P; Valeri G; Midiri M; Pepe A
    Circ Cardiovasc Imaging; 2015 Aug; 8(8):e003230. PubMed ID: 26253625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of global strain values of myocardium in beta-thalassemia major patients with iron load using specific feature tracking in cardiac magnetic resonance imaging.
    Rezaeian N; Mohtasham MA; Khaleel AJ; Parnianfard N; Kasani K; Golshan R
    Int J Cardiovasc Imaging; 2020 Jul; 36(7):1343-1349. PubMed ID: 32346846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study.
    Ambati SR; Randolph RE; Mennitt K; Kleinert DA; Weinsaft JW; Giardina PJ
    Am J Hematol; 2013 Aug; 88(8):652-6. PubMed ID: 23640778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance.
    Kirk P; Carpenter JP; Tanner MA; Pennell DJ
    J Cardiovasc Magn Reson; 2011 Jan; 13(1):8. PubMed ID: 21241474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging.
    Seldrum S; Pierard S; Moniotte S; Vermeylen C; Vancraeynest D; Pasquet A; Vanoverschelde JL; Gerber BL
    J Cardiovasc Magn Reson; 2011 Apr; 13(1):23. PubMed ID: 21518461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.